From a macro perspective, the rckt stock forecast benefits from favorable regulatory environments in biotech approvals. Traders note a rising trend in biotech ETFs, suggesting rckt could ride sector momentum toward the $5.50 psychological level. Rocket Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. It seems likely that the business is content with its current spending, as the cash burn rate stayed steady over the last twelve months. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . Now that conditions appear more favorable, it’s a good time to look at small-cap stocks. Here are three that stand out. Analysts see biotech M&A activity as an upside driver in the rckt stock forecast. Acquisition rumors often stimulate speculative moves, and rckt’s valuation positions it as a potential target.